Communiqués Editas Medicine, Inc.

Actions

EDIT

US28106W1036

Temps réel estimé Cboe BZX Autres places de cotation 15:40:38 16/07/2024			Varia. 5j.	Varia. 1 janv.
5,755 ^USD	+2,58 %		+16,39 %	-44,62 %

27/06	Editas Medicine, Inc. annonce la démission d'Akshay Vaishnaw du Conseil d'administration avec effet au 30 juin 2024	CI
14/06	Editas Medicine déclare que son traitement potentiel de la drépanocytose par édition de gènes a été bien toléré lors d'un essai de phase 1/2	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Editas Medicine Reports New Safety And Efficacy Data From The RUBY Trial Of Reni-Cel In 18 Patients With Sickle Cell Disease, Presented At The European Hematology Association Annual Congress	17/06	AQ
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress	14/06	GL
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress	14/06	GL
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June	14/05	GL
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June	14/05	AQ
Editas Medicine Preclinical Data Highlights Advancement Of In Vivo Gene Editing Medicine Technologies at The American Society Of Gene And Cell Therapy Annual Meeting	13/05	AQ
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting	10/05	GL
Editas: Q1 Earnings Snapshot	08/05	AQ
Editas Medicine Announces First Quarter 2024 Results and Business Updates	08/05	GL
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events	02/05	GL
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05	GL
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	22/04	GL
Editas Medicine : April 2024 Corporate Presentation	12/04	PU
Editas Medicine : Corporate Effectiveness Report April 2024	12/04	PU
Editas: Q4 Earnings Snapshot	28/02	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02	AQ
Editas Medicine to Participate in Upcoming Investor Conferences	31/01	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Editas Medicine, Inc.

Actions

EDIT

US28106W1036

Communiqués

Filtres